T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.
Immunity
View this publicationImmunity
View this publicationJournal of CME
View this publicationJournal of molecular cell biology
View this publicationClinical nuclear medicine
View this publicationJournal of leukocyte biology
View this publicationJournal of clinical medicine
View this publicationFrontiers in genetics
View this publicationEuropean journal of immunology
View this publicationFrontiers in tropical diseases
View this publicationCancer cell international
View this publication